Patent Review Method Should Consider Public Interest Factors - Torricelli
Executive Summary
Review mechanisms for the extension of "pipeline" drug patents should take into account public interest factors, Sen. Torricelli (D-N.J.) told a House Judiciary/Intellectual Property Subcommittee hearing July 1.
You may also be interested in...
Rx Rebates, Gifts To Physicians Would Be Public Under Torricelli Proposal
Prescription drug rebates that manufacturers pay to PBMs would be public information under a legislative proposal by Sen. Bob Torricelli (D-N.J.)
Rx Rebates, Gifts To Physicians Would Be Public Under Torricelli Proposal
Prescription drug rebates that manufacturers pay to PBMs would be public information under a legislative proposal by Sen. Bob Torricelli (D-N.J.)
PTO Not Qualified To Judge FDA Review of "Pipeline" Products - Barr
Proposed legislation to reform the drug patent term restoration process could undercut FDA's "scientific judgements" by transferring undue authority to the Patent and Trademark Office, Sen. Leahy (D-Vt.) said during the Senate Judiciary committee's Aug. 4 hearing, "Pipeline Drugs: Proposed Remedies for Relief in S 1172."